Reserves, functional, immunoregulatory, and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes

Stem Cells and Development

Volumn 19, Issue 7, 2010, Pages 1043-1054

  Klaus, Mirjam ^a   Stavroulaki, Emily ^a   Kastrinaki, Maria Christina ^a   Fragioudaki, Persefoni ^a   Giannikou, Krinio ^a   Psyllaki, Maria ^a   Pontikoglou, Charalampos ^a   Tsoukatou, Debbie ^b   Mamalaki, Clio ^b   Papadaki, Helen A ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b INSTITUTE OF MOLECULAR BIOLOGY AND BIOTECHNOLOGY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; AGGRECAN; BETA1 INTEGRIN; CD146 ANTIGEN; CD3 ANTIGEN; COLLAGEN TYPE 2; ENDOGLIN; HERMES ANTIGEN; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STROMAL CELL DERIVED FACTOR 1ALPHA; THY 1 ANTIGEN; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; CYTOKINE;

ADIPOCYTE; ADULT; AGED; ARTICLE; BONE MARROW; CARTILAGE CELL; CELL CULTURE; CELL FRACTIONATION; CELL PROLIFERATION; CLINICAL ARTICLE; COLONY FORMING UNIT F; CONTROLLED STUDY; CYTOGENETICS; DISEASE ASSOCIATION; FLUORESCENCE IN SITU HYBRIDIZATION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IMMUNOREGULATION; INFLAMMATION; INHIBITION KINETICS; MESENCHYMAL STEM CELL; MYELODYSPLASTIC SYNDROME; OSTEOBLAST; PATIENT; PRIORITY JOURNAL; REFRACTORY ANEMIA; T LYMPHOCYTE; TRISOMY; TRISOMY 7; ANIMAL; BONE MARROW CELL; CELL DIFFERENTIATION; CHROMOSOME ABERRATION; CYTOLOGY; HEMATOPOIETIC STEM CELL; IMMUNOLOGY; MESENCHYMAL STROMA CELL; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANIMALS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CHROMOSOME ABERRATIONS; CYTOKINES; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOPHENOTYPING; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; T-LYMPHOCYTES;

EID: 77954928083     PISSN: 15473287     EISSN: None     Source Type: Journal    
DOI: 10.1089/scd.2009.0286     Document Type: Article

References (58)

1. Mufti GJ. (2004). Pathobiology, classification, and diagnosis of myelodysplastic syndrome. Best Pract Res Clin Haematol 17: 543-557.
2. Nimer SD. (2008). Myelodysplastic syndromes. Blood 111: 4841-4851.
3. Nolte F and WK Hofmann. (2008). Myelodysplastic syndromes: molecular pathogenesis and genomic changes. Ann Hematol 87: 777-795.
4. Kerbauy DB and HJ Deeg. (2007). Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol 35: 1739-1746.
5. Tauro S, MD Hepburn, DT Bowen and MJ Pippard. (2001). Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes. Haematologica 86: 1038-1045.
6. Tauro S, MD Hepburn, CM Peddie, DT Bowen and MJ Pippard. (2002). Functional disturbance of marrow stromal microenvironment in the myelodysplastic syndromes. Leukemia 16: 785-790.
7. Parker JE and GJ Mufti. (2004). The myelodysplastic syndromes: a matter of life or death. Acta Haematol 111: 78-99.
8. Aizawa S, M Nakano, O Iwase, M Yaguchi, M Hiramoto, H Hoshi, R Nabeshima, D Shima, H Handa and K Toyama. (1999). Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. Leuk Res 23: 239-246.
9. Dunbar CE and Y Saunthararajah. (2000). Myelodysplastic Syndromes. In: Bone Marrow Failure Syndromes. Young NS, ed. W.B. Saunders Company, Philadelphia, pp 69-98.
10. Sloand EM and K Rezvani. (2008). The role of the immune system in myelodysplasia: implications for therapy. Semin Hematol 45: 39-48.
11. Parker JE and GJ Mufti. (1998). Ineffective haematopoiesis and apoptosis in myelodysplastic syndromes. Br J Haematol 101: 220-230.
12. Liesveld JL, CT Jordan and GL Phillips. (2004). The hematopoietic stem cell in myelodysplasia. Stem Cells 22: 590-599.
13. Pittenger MF, AM Mackay, SC Beck, RK Jaiswal, R Douglas, JD Mosca, MA Moorman, DW Simonetti, S Craig and DR Marshak. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147.
14. Bianco P, M Riminucci, S Gronthos and PG Robey. (2001). Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells 19: 180-192.
15. Pontikoglou C, B Delorme and P Charbord. (2008). Human bone marrow native mesenchymal stem cells. Regen Med 3: 731-741.
16. Sotiropoulou P and M Papamichail. (2007). Immune properties of mesenchymal stem cells. Methods Mol Biol 407: 225-243.
17. Uccelli A, V Pistoia and L Moretta. (2007). Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol 28: 219-226.
18. Jones BJ and SJ McTaggart. (2008). Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp Hematol 36: 733-741.
19. Martin-Rendon E and SM Watt. (2003). Stem cell plasticity. Br J Haematol 122: 877-891.
20. Soenen-Cornu V, C Tourino, ML Bonnet, M Guillier, S Flamant, R Kotb, A Bernheim, JH Bourhis, C Preudhomme, P Fenaux and AG Turhan. (2005). Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short-and long-term hematopoiesis in vitro. Oncogene 24: 2441-2448.
21. Flores-Figueroa E, JJ Montesinos, P Flores-Guzman G Gutierrez-Espindola, RM rana-Trejo, S Castillo-Medina, A Perez-Cabrera, E Hernandez-Estevez, L Arriaga and H Mayani. (2008). Functional analysis of myelodysplastic syndromes-derived mesenchymal stem cells. Leuk Res 32: 1407-1416.
22. Flores-Figueroa E, RM rana-Trejo, G Gutierrez-Espindola, A Perez-Cabrera and H Mayani. (2008). Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization. Leuk Res 29: 215-224.
23. Blau O, WK Hofmann, CD Baldus, G Thiel, V Serbent, E Schumann, E Thiel and LW Blau. (2007). Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia. Exp Hematol 35: 221-229.
24. Han Q, Z Sun, L Liu, B Chen, Y Cao, K Li and RC Zhao. (2007). Impairment in immuno-modulatory function of Flk1(+)CD31(?) CD34(?) MSCs from MDS-RA patients. Leuk Res 31: 1469-1478.
25. Varga G, J Kiss, J Varkonyi, V Vas, P Farkas, K Palocz and F Uher. (2007). Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes. Pathol Oncol Res 13: 311-319.
26. Lopez-Villar O, JL Garcia, FM Sanchez-Guijo, C Robledo, EM Villaron, P Hernandez-Camp, N Lopez-Holgado, M ez-Campelo, MV Barbado, JA Perez-Simon, JM Hernandez-Rivas, JF San-Miguel and MC Del Canizo. (2009). Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q-syndrome. Leukemia 23: 664-672.
27. Jaffe ES, NL Harris, H Stein and JW Vardiman. (2001). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth Edition. IARC Press, Lyon.
28. Greenberg P, C Cox, MM LeBeau, P Fenaux, P Morel, G Sanz, T Vallespi, T Hamblin, D Oscier, K Ohyashiki, K Toyama, C Aul, G Mufti and J Bennett. (1997). International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89: 2079-2088.
29. Delorme B and P Charbord. (2007) Culture and characterisation of human bone marrow mesenchymal stem cells. In: Methods in Molecular Medicine, 2nd ed.: Tissue Engineering. Hauser H, M Fussenegger eds. Humana Press Inc., Totowa, NJ, pp 67-82.
30. Gronthos S, SE Graves and PJ Simmons. (1998). Isolation, purifi-cation and in vitro manipulation of human bone marrow stromal precursor cells. In: Marrow Stromal Cell Culture. Beresford JN, ME Owen, eds. Cambridge University Press, Cambridge, pp 26-42.
31. Kastrinaki MC, I Andreakou, P Charbord and HA Papadaki. (2008). Isolation of human bone marrow mesenchymal stem cells using different membrane markers: comparison of colony/cloning efficiency, differentiation potential, and molecular profile. Tissue Eng Part C Methods 14: 333-339.
32. Kastrinaki MC, P Sidiropoulos, S Roche, J Ringe, S Lehmann, H Kritikos, VM Vlahava, B Delorme, GD Eliopoulos, C Jorgensen, P Charbord, T Haupl, DT Boumpas and HA Papadaki. (2008). Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis. Ann Rheum Dis 67: 741-749.
33. In't Anker PS, WA Noort, SA Scherjon, KC Kleijburg-van der, AB Kruisselbrink, RL van Bezooijen, W Beekhuizen, R Willemze, HH Kanhai and WE Fibbe. (2003). Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica 88: 845-852.
34. Rizzo S, J Scopes, MO Elebute, HA Papadaki, EC Gordon-Smith and FM Gibson. (2002). Stem cell defect in aplastic anemia: reduced long term culture-initiating cells (LTC-IC) in CD34+ cells isolated from aplastic anemia patient bone marrow. Hematol J 3: 230-236.
35. Di Nicola M, C Carlo-Stella, M Magni, M Milanesi, PD Longoni, P Matteucci, S Grisanti and AM Gianni. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99: 3838-3843.
36. Klyushnenkova E, JD Mosca, V Zernetkina, MK Majumdar, KJ Beggs, DW Simonetti, RJ Deans and KR McIntosh. (2005). T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 12: 47-57.
37. Fonatsch C, M Schaadt, H Kirchner and V Diehl. (1980). A possible correlation between the degree of karyotype aberrations and the rate of sister chromatid exchanges in lymphoma lines. Int J Cancer 26: 749-756.
38. Shaffer LG and N Tommerup eds. (2005). ISCN 2005: An International System for Human Cytogenetics Nomenclature. S. Karger, Basel, Switzerland.
39. Deeg HJ, C Beckham, MR Loken, E Bryant, M Lesnikova, HM Shulman and T Gooley. (2000). Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leuk Lymphoma 37: 405-414.
40. LeBlanc K and O Ringden. (2007). Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 262: 509-525.
41. Zhi-Gang Z, L Wei-Ming, C Zhi-Chao, Y Yong and Z Ping. (2008). Immunosuppressive properties of mesenchymal stem cells derived from bone marrow of patient with hematological malignant diseases. Leuk Lymphoma 49: 2187-2195.
42. Ramakrishnan A, N Awaya, E Bryant and B Torok-Storb. (2006). The stromal component of the marrow microenvironment is not derived from the malignant clone in MDS. Blood 108: 772-773.
43. Vallespi T, M Imbert, C Mecucci, C Preudhomme and P Fenaux. (1998). Diagnosis, classification, and cytogenetics of myelodysplastic syndromes. Haematologica 83: 258-275.
44. Mareschi K, I Ferrero, D Rustichelli, S Aschero, L Gammaitoni, M Aglietta, E Madon and F Fagioli. (2006). Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow. J Cell Biochem 97: 744-754.
45. Bernardo ME, N Zaffaroni, F Novara, AM Cometa, MA Avanzini, A Moretta, D Montagna, R Maccario, R Villa, MG Daidone, O Zuffardi and F Locatelli. (2007). Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 67: 9142-9149.
46. Ma ESK and TSK Wan. (2002). Trisomy 5. Atlas Genet Cyto ge net Oncol Haematol. http://AtlasGeneticsOncology.org/Anomalies/tri5ID1255.html
47. Teyssier JR and D Ferre. (1989). Frequent clonal chromosomal changes in human non-malignant tumors. Int J Cancer 44: 828-832.
48. Mandahl N, YS Jin, S Heim, H Willen, J Wennerberg, A Biorklund and F Mitelman. (1990). Trisomy 5 and loss of the Y chromosome as the sole cytogenetic anomalies in a cavernous hemangioma/angiosarcoma. Genes Chromosomes Cancer 1: 315-316.
49. Mark J, R Dahlenfors, G Stenman and A Nordquist. (1990). Chromosomal patterns in Warthin's tumor. A second type of human benign salivary gland neoplasm. Cancer Genet Cytogenet 46: 35-39.
50. Fletcher JA, C Henkle, L Atkins, AE Rosenberg and CC Morton. (1992). Trisomy 5 and trisomy 7 are nonrandom aberrations in pigmented villonodular synovitis: confirmation of trisomy 7 in uncultured cells. Genes Chromosomes Cancer 4: 264-266.
51. Ozisik YY, R Morgan, A Peier, AM Meloni and AA Sandberg. (1994). Trisomy 5 in long-term cultures from bone marrow of patients with solid tumors. Cancer Genet Cytogenet 78: 207-209.
52. Elfving P, JC Cigudosa, R Lundgren, J Limon, N Mandahl, U Kristoffersson and F Mitelman. (1990). Trisomy 7, trisomy 10, and loss of the Y chromosome in short-term cultures of normal kidney tissue. Cytogenet Cell Genet 3: 123-125.
53. Mertens F, C Orndal, N Mandahl, S Heim, HF Bauer, A Rydholm, A Tufvesson, H Wille and F Mitelman. (1993). Chromosome aberrations in tenosynovial giant cell tumors and nontumorous synovial tissue. Genes Chromosomes Cancer 6: 212-217.
54. Dessen P, S Knuutila and JL Huret. (2004). Chromosome. Atlas Genet Cytogenet Oncol Haematol. http://atlasgenetics oncology.org/Indexbychrom/idxa-7. html
55. Dessen P and JL Huret. (2009). Chromosome. Atlas Genet Cytogenet Oncol Haematol. http://atlasgeneticsoncology.org/Indexbychrom/idxa-7.html
56. Broberg K, S Toksvig-Larsen, A Lindstrand and F Mertens. (2001). Trisomy 7 accumulates with age in solid tumors and nonneoplastic synovia. Genes Chromosomes Cancer 30: 310-315.
57. Kinne RW, E Kunisch, V Beensen, T Zimmermann, F Emmrich, P Petrow, W Lungershausen, G Hein, RK Braun, M Foerster, C Kroegel, R Winter, E Liesaus, RA Fuhrmann, A Roth, U Claussen and T Liehr. (2003) Synovial fibroblasts and synovial macrophages from patients with rheumatoid arthritis and other inflammatory joint diseases show chromosomal aberrations. Genes Chromosomes Cancer 38: 53-67.
58. Johansson B, S Heim, N Mandahl, F Mertens and F Mitelman. (1993). Trisomy 7 in nonneoplastic cells. Genes Chromosomes Cancer 6: 199-205.